NNFN Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MannKind Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.18 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.31 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| NNFN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | -1.9% | -0.5% |
| 1Y | n/a | 91.7% | 2.8% |
Return vs Industry: Insufficient data to determine how NNFN performed against the Swiss Biotechs industry.
Return vs Market: Insufficient data to determine how NNFN performed against the Swiss Market.
Price Volatility
| NNFN volatility | |
|---|---|
| NNFN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 12.7% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: NNFN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine NNFN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 413 | Michael Castagna | www.mannkindcorp.com |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
MannKind Corporation Fundamentals Summary
| NNFN fundamental statistics | |
|---|---|
| Market cap | CHF 1.62b |
| Earnings (TTM) | CHF 10.15m |
| Revenue (TTM) | CHF 214.82m |
159.8x
P/E Ratio7.6x
P/S RatioIs NNFN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNFN income statement (TTM) | |
|---|---|
| Revenue | US$248.37m |
| Cost of Revenue | US$71.30m |
| Gross Profit | US$177.08m |
| Other Expenses | US$165.34m |
| Earnings | US$11.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.043 |
| Gross Margin | 71.29% |
| Net Profit Margin | 4.73% |
| Debt/Equity Ratio | -100.8% |
How did NNFN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/28 12:42 |
| End of Day Share Price | 2024/07/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MannKind Corporation is covered by 26 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Russo | Baird |
| Stephen V. Byrne | BofA Global Research |
| null null | BTIG |